[go: up one dir, main page]

CA2326406A1 - Adjuvants faisant office de vaccins permettant l'immunisation contre les melanomes - Google Patents

Adjuvants faisant office de vaccins permettant l'immunisation contre les melanomes Download PDF

Info

Publication number
CA2326406A1
CA2326406A1 CA002326406A CA2326406A CA2326406A1 CA 2326406 A1 CA2326406 A1 CA 2326406A1 CA 002326406 A CA002326406 A CA 002326406A CA 2326406 A CA2326406 A CA 2326406A CA 2326406 A1 CA2326406 A1 CA 2326406A1
Authority
CA
Canada
Prior art keywords
antigen
cells
peptide
tumor
pulsed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002326406A
Other languages
English (en)
Inventor
Thomas F. Gajewski
Francesca Fallarino
Matthew L. Sherman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Arch Development Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/064,964 external-priority patent/US6080399A/en
Application filed by Individual filed Critical Individual
Publication of CA2326406A1 publication Critical patent/CA2326406A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention se rapporte à des procédés permettant d'induire la production de lymphocytes T cytolytiques dirigés contre les tumeurs malignes ou un agent infectieux chez un mammifère, et de traiter ces cas pathologiques de façon à minimiser les effets secondaires nocifs et à améliorer considérablement et de façon étonnante le traitement des mélanomes métastatiques.
CA002326406A 1998-04-23 1999-04-23 Adjuvants faisant office de vaccins permettant l'immunisation contre les melanomes Abandoned CA2326406A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/064,964 US6080399A (en) 1998-04-23 1998-04-23 Vaccine adjuvants for immunotherapy of melanoma
US09/168,832 1998-10-08
US09/064,964 1998-10-08
US09/168,832 US6716422B1 (en) 1998-04-23 1998-10-08 Vaccine adjuvants for immunotherapy of melanoma
PCT/US1999/008889 WO1999053949A2 (fr) 1998-04-23 1999-04-23 Adjuvants faisant office de vaccins permettant l'immunisation contre les melanomes

Publications (1)

Publication Number Publication Date
CA2326406A1 true CA2326406A1 (fr) 1999-10-28

Family

ID=26745085

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002326406A Abandoned CA2326406A1 (fr) 1998-04-23 1999-04-23 Adjuvants faisant office de vaccins permettant l'immunisation contre les melanomes

Country Status (6)

Country Link
EP (1) EP1071450A2 (fr)
JP (1) JP2002512202A (fr)
AU (1) AU767208B2 (fr)
CA (1) CA2326406A1 (fr)
NZ (1) NZ507829A (fr)
WO (1) WO1999053949A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524587B1 (en) * 1998-05-05 2003-02-25 Bruce W. Lyday Hyperthermia and immunotherapy for leukemias lymphomas, and solid tumors
FR2795074A1 (fr) * 1999-05-21 2000-12-22 Inst Nat Sante Rech Med Polypeptides transporteurs d'acides amines, et en particulier du glutamate, et procedes de criblage de composes inhibiteurs ou activateurs de l'activite de transport
DK1408106T3 (da) 2002-10-11 2007-06-11 Sentoclone Ab Cancer immunterapi
WO2004069272A2 (fr) * 2003-02-05 2004-08-19 Movecare Ltd Combinaison d'adjuvants destinee a l'immunisation d'un mammifere et comprenant il et il12
WO2007071389A1 (fr) 2005-12-21 2007-06-28 Sentoclone Ab Méthode de traitement de cancer disséminé
EP1966369B1 (fr) 2005-12-21 2010-10-06 Sentoclone AB Methode pour la proliferation de lymphocytes t reactifs a une tumeur a des fins d'immunotherapie pour des patients atteints de cancer
US8101173B2 (en) 2005-12-21 2012-01-24 Sentoclone International Ab Method for treating urinary bladder cancer
WO2007071390A1 (fr) * 2005-12-21 2007-06-28 Sentoclone Ab Méthode de traitement de mélanome malin
WO2009133863A1 (fr) * 2008-04-28 2009-11-05 国立大学法人浜松医科大学 Immunostimulant comprenant l’agoniste ep1
US20110076689A1 (en) * 2008-05-29 2011-03-31 Sysmex Corporation PRIMER FOR DETECTING TYROSINASE mRNA
JP2012025694A (ja) * 2010-07-23 2012-02-09 Asahi Kasei Kuraray Medical Co Ltd 癌治療剤
WO2019136305A1 (fr) * 2018-01-04 2019-07-11 Neumedicines Inc. Thérapies à base de cellules et par inhibiteurs de points de contrôle immunitaires combinées à il-12 pour le traitement du cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1152397A (en) * 1995-12-20 1997-07-14 Board Of Trustees Of The Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells

Also Published As

Publication number Publication date
WO1999053949A9 (fr) 2000-05-25
AU767208B2 (en) 2003-11-06
WO1999053949A3 (fr) 2000-03-09
AU3865999A (en) 1999-11-08
WO1999053949A2 (fr) 1999-10-28
EP1071450A2 (fr) 2001-01-31
JP2002512202A (ja) 2002-04-23
NZ507829A (en) 2004-03-26

Similar Documents

Publication Publication Date Title
US6716422B1 (en) Vaccine adjuvants for immunotherapy of melanoma
Kündig et al. Fibroblasts as efficient antigen-presenting cells in lymphoid organs
Vierboom et al. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes
Hu et al. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy
van den Broeke et al. Dendritic cell-induced activation of adaptive and innate antitumor immunity
KR100603075B1 (ko) Ｍｈｃ 클래스 ⅱ 리간드의 예방접종을 위한 항항원체로의이용과 ｌａｇ-3의 암 치료에의 이용
US20080305131A1 (en) Cancer Immunotherapy with Semi-Allogeneic Cells
Fallarino et al. Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide‐pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin‐12
AU767208B2 (en) Combination of antigen pulsed APCS and interleukin 12 for tumor and viral therapy
JP2001509135A (ja) 混合リンパ球と組み合わせた腫瘍細胞を用いるガン免疫療法
US20020006413A1 (en) Genetically engineered tumor cell vaccines
TW201805012A (zh) 利用前列腺癌相關抗原之腫瘤疫苗接種之組合物及方法
US6183734B1 (en) Inhibition of tumor cell growth by administration of B7-transfected cells
Nawrocki et al. Genetically modified tumour vaccines–where we are today
Kaufman et al. Strategies for cancer therapy using carcinoembryonic antigen vaccines
US20040028663A1 (en) Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer
PT1093465E (pt) ''processo para produzir ou intensificar uma resposta de células t contra uma célula alvo, utilizando um complexo compreendendo uma molécula hla de classe i e meios de ligação''
EP1670899A2 (fr) Vaccins contre le cancer, des affections auto-immunes et des infections
JP2004507445A (ja) 白血病、リンパ腫、及び充実性腫瘍のための温熱療法及び免疫療法
US7378495B2 (en) PTH-rP related peptide cancer therapeutics
AU2004200444A1 (en) Vaccine adjuvants for immunotherapy of melanoma
US20050180951A1 (en) Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer
Wang et al. Generating renal cancer-reactive T cells using dendritic cells (DCs) to present autologous tumor
CN101812126B (zh) 一种新的hPEBP4蛋白来源的HLA-A2限制性表位多肽及其应用
EP1696950A2 (fr) Vaccin comprenant une angiomotine ou un polynucleotide codant une angiomotine et son utilisation pour le traitement des maladies angiogeniques

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued